PARIS – Implanet SA won approval from its founding shareholders to acquire a majority stake in spinal implant manufacturer Orthopaedic & Spine Development SAS (OSD). Implanet’s bid is aimed at acquiring majority control, and potentially the entire share capital, of Avignon, France-based OSD, valued at $5 million. OSD’s founding shareholders, representing 71.5% of the capital, have already committed to respond favorably to the bid, thus confirming the principles behind this merger.
PARIS – Whitelab Genomics SAS has signed a partnership agreement with Genethon, a French research center in the field of gene therapy, to ramp up development of genetic therapy techniques using artificial intelligence (AI). As part of this partnership, Genethon will use the Whitelab Genomics Catalyst platform to develop new capsids.
Medtronic plc obtained the CE mark for its Sensight directional lead system for deep brain stimulation (DBS) for movement disorders and epilepsy, which is designed to be used with the company’s Percept PC DBS device. Percept received U.S. FDA clearance in June 2020 and CE mark in January 2020.
A large-scale metabolomics study of blood samples from 11,000 people has identified common biological links among a number of chronic non-communicable diseases, opening up the possibility of countering multiple diseases simultaneously.
LONDON – Astrazeneca plc’s COVID-19 vaccine is safe and effective and the benefits well outweigh any risks, according to a review carried out by the EMA, following reports of blood clots in people who received the vaccine.
A large-scale metabolomics study of blood samples from 11,000 people has identified common biological links among a number of chronic non-communicable diseases, opening up the possibility of countering multiple diseases simultaneously.
LONDON – Following circulating tumor cells and cell-free tumor DNA, a new type of liquid biopsy is poised for commercial rollout after Datar Cancer Genetics Ltd. secured CE marking for Trublood, a method for isolating tumor cell clusters. In fact, the clusters do not consist solely of tumor cells, but can also include endothelial cells, erythrocytes, stromal cells, leukocytes, platelets, and cancer-associated fibroblasts. They are held together by cell-to cell-adhesion proteins.
PARIS – Carmat SA has just completed a capital increase of $66.4 million to boost development of its total artificial heart. The Aeson system was awarded CE marking four months ago, as a total bridge to transplantation for patients suffering with end-stage biventricular heart failure who are not eligible for maximal medical therapy or a left ventricular assist device (LVAD), and who are likely to undergo a heart transplant within 180 days of the implantation.
A large-scale metabolomics study of blood samples from 11,000 people has identified common biological links among a number of chronic non-communicable diseases, opening up the possibility of countering multiple diseases simultaneously.
According to the latest annual overview published by trade association France Biotech, French med-tech, biotech, and e-health companies have adapted rapidly to the COVID-19 pandemic. Many French health care companies have faced real difficulties in all areas of procurement, R&D, and sales. As of February, a quarter of these French companies were redirecting their research activity towards the coronavirus.